Assertio Holdings, Inc.

Assertio is a specialty pharmaceutical company focused on acquiring and optimizing commercial-stage assets, particularly in the areas of neurology, inflammation, and pain management. The company operates under a lean, acquisition-driven business model, seeking to maximize the value of established brands through targeted marketing and lifecycle management rather than traditional early-stage drug discovery. Following its 2023 acquisition of Spectrum Pharmaceuticals, Assertio expanded its portfolio into oncology with the addition of Rolvedon. The company has undergone significant transformation in recent years, shifting from its legacy as Depomed to a streamlined entity focused on maintaining a diversified portfolio of high-margin pharmaceutical products.